Exelixis
EXEL
#1488
Rank
NZ$25.72 B
Marketcap
NZ$103.84
Share price
0.78%
Change (1 day)
46.49%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): NZ$5.74

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$5.87. In 2025 the company made an earnings per share (EPS) of NZ$5.14.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$5.7411.6%
2025NZ$5.14
2023NZ$1.1614.61%
2022NZ$1.01-22.97%
2021NZ$1.32100%
2020NZ$0.66-65.09%
2019NZ$1.89-53.91%
2018NZ$4.09333.96%
2017NZ$0.94-260.61%
2016NZ-$0.59-58.75%
2015NZ-$1.42-42.45%
2014NZ-$2.475.3%
2013NZ-$2.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$15.53 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$1.35-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$28.85 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.38-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$2.25-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$8.07 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$5.69-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$25.29-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.49-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA